TY - JOUR
AU - Närhi, Fiina
AU - Moonesinghe, S. Ramani
AU - Shenki, Susan D.
AU - Drake, Thomas M.
AU - Mulholland, Rachel H.
AU - Donegan, Cara
AU - Dunning, Jake
AU - Fairfield, Cameron J.
AU - Girvan, Michelle
AU - Hardwick, Hayley E.
AU - Ho, Antonia
AU - Leeming, Gary
AU - Nguyen-Van-Tam, Jonathan S.
AU - Pius, Riinu
AU - Russell, Clark D.
AU - Shaw, Catherine A.
AU - Spencer, Rebecca G.
AU - Turtle, Lance C.W.
AU - Openshaw, Peter J.M.
AU - Baillie, J. Kenneth
AU - Harrison, Ewen M.
AU - Semple, Malcolm G.
AU - Docherty, Annemarie B.
AU - ISARIC4C Investigators
PY - 2022
DA - April
TI - Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study
JO - The Lancet Digital Health
EP - e234
VL - 4
IS - 4
DO - http://dx.doi.org/10.1016/S2589-7500(22)00018-8
AB - Background: Dexamethasone was the first intervention proven to reduce mortality in patients with COVID-19 being treated in hospital. We aimed to evaluate the adoption of corticosteroids in the treatment of COVID-19 in the UK after the RECOVERY trial publication on June 16, 2020, and to identify discrepancies in care.
PB - Elsevier
UR - http://eprints.gla.ac.uk/263165/
KW - Coronavirus (COVID-19)
KW - Health inequalities
KW - Hospital care
ER